Evidence map›Paper›PMID 20491793›Full record

ArticleClinical and experimental immunology2010

Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome.

R Bertelli, A Trivelli, A Magnasco, M Cioni, M Bodria, A Carrea, G Montobbio, G Barbano, G M Ghiggeri

Registry-linked trialOpen access · greenAbstract readComparative Study
In one paragraph

Article in Clinical and experimental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02455908 (Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02455908 phase1 / phase2completednot on this mapstarted 2012, after this paper: background citation

Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome

TypeinterventionalSponsorIstituto Giannina GasliniRan2012 to 2012Enrolled5ConditionsNephrotic SyndromeArmsProleukin®
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Rituximab in children with resistant idiopathic nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2012
    Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Genetics of childhood steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2017
    Review
  9. Review
  10. The glomerular permeability factors in idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Nephrotic syndrome in children: from bench to treatment.International journal of nephrology · 2011
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

R BertelliDivision of Nephrology and Laboratory on Pathophysiology of Uremia, Istituto Giannina Gaslini IRCCS, Genova, Italy.
A Trivelli
A Magnasco
M Cioni
M Bodria
A Carrea
G Montobbio
G Barbano
G M Ghiggeri
Istituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanism responsible for proteinuria in non-genetic idiopathic nephrotic syndrome (iNS) is unknown. Animal models suggest an effect of free radicals on podocytes, and indirect evidence in humans confirm this implication. We determined the oxidative burst by blood CD15+ polymorphonucleates (PMN) utilizing the 5-(and-6)-carboxy-2',7'-dichlorofluorescin diacetate (DCF-DA) fluorescence assay in 38 children with iNS. Results were compared with PMN from normal subjects and patients with renal pathologies considered traditionally to be models of oxidative stress [six anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, seven post-infectious glomerulonephritis]. Radicals of oxygen (ROS) production was finally determined in a patient with immunodeficiency, polyendocrinopathy, enteropathy X-linked (IPEX) and in seven iNS children after treatment with Rituximab. Results demonstrated a 10-fold increase of ROS production by resting PMN in iNS compared to normal PMN. When PMN were separated from other cells, ROS increased significantly in all conditions while a near-normal production was restored by adding autologous cells and/or supernatants in controls, vasculitis and post-infectious glomerulonephritis but not in iNS. Results indicated that the oxidative burst was regulated by soluble factors and that this regulatory circuit was altered in iNS. PMN obtained from a child with IPEX produced 100 times more ROS during exacerbation of clinical symptoms and restored to a near normal-level in remission. Rituximab decreased ROS production by 60%. In conclusion, our study shows that oxidant production is increased in iNS for an imbalance between PMN and other blood cells. Regulatory T cells (Tregs) and CD20 are probably involved in this regulation. Overall, our observations reinforce the concept that oxidants deriving from PMN are implicated in iNS.

Indexed as

Respiratory BurstAdolescentAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisChildChild, PreschoolDrug Therapy, CombinationFemaleFluoresceinsFluorescent DyesGlomerulonephritisHumansImmunosuppressive AgentsKidneyMaleAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DeriveddiacetyldichlorofluoresceinFluoresceinsFluorescent DyesImmunosuppressive AgentsReactive Oxygen SpeciesRituximab

Identifiers

PMID20491793
PMCPMC2940160
OpenAlexW1491188868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.